Teleflex Inc at Morgan Stanley Healthcare Conference Transcript
Thank you. Let's go ahead and get started here as we kind of progress into the lunch hour. My name is David Lewis, Medical Device Analyst for Morgan Stanley. As we've been saying, thanks for joining us here for the third day of our conference. But just make sure you go to Morgan Stanley research disclosure website and check out fun and interesting facts about me and my 5-year-old, who's just in kindergarten. That's not up there but important information, I think.
So let's start strategic and sort of work our way -- sorry, we have Teleflex here. I should've mentioned. Liam Kelly and Thomas Powell, both CEO and CFO, respectively.
Questions & Answers
So Liam, we've talked about for -- or the early period of our coverage of Teleflex, it was all about cost and margin. In the last couple of years, the debate has shifted much more specifically to growth. I wanted to just say you talked about the LRP growth rate was sort of 6% to 7%.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |